UCB Phase III RA data

UCB (Euronext:UCB) said preliminary data from a placebo-controlled Phase III (Study 011) trial showed that CDP 870 significantly improved ACR20 scores at 24 weeks, the primary endpoint, in 220 rheumatoid arthritis (RA) patients previously treated with methotrexate and other DMARDs. UCB said additional data from the U.S. and European trial are expected in late 2005 or early 2006. ...